Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData, Phase II drugs for Primary Sclerosing Cholangitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Bexotegrast LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bexotegrast overview

Bexotegrast (PLN-74809) is under development for the treatment of primary sclerosing cholangitis, idiopathic pulmonary fibrosis (IPF), liver fibrosis and COVID-19-related acute respiratory distress syndrome. The drug candidate acts by targeting integrin alpha 5 beta 6 and integrin alpha 5 beta 1.

Pliant Therapeutics overview

Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of fibrosis. The company’s pipeline products include PLN-74809, PLN-101095, PLN-101325 and PLN-1474. Its pipeline candidates treat idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), solid tumors, other muscular dystrophies and NASH-associated liver fibrosis. The company is also evaluating therapies to treat muscular dystrophy, solid tumors, and cancer. It works in partnership with Novartis AG and other institutions, universities, medical centers, physicians and researchers to develop its products. Pliant Therapeutics is headquartered in South San Francisco, California, the US.

For a complete picture of Bexotegrast’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.